CRISPR Therapeutics and Intellia Therapeutics stand out as two leading names in the gene-editing space, both relying on CRISPR/Cas9 technology to make precise changes to DNA. While they operate from the same foundational platform, their development stages, pipeline focuses, and market capitalizations set them apart. For investors considering biotechnology exposure, this comparison shows how performance trends, momentum, and upcoming catalysts can play out differently even within the same sector. Those distinctions help clarify risk levels, investment timelines, and positioning in a volatile area of healthcare.
CRISPR Therapeutics, based in Switzerland, is best known for CASGEVY, the first CRISPR/Cas9 therapy approved by the U.S. FDA. Developed with Vertex Pharmaceuticals, it treats sickle cell disease and transfusion-dependent beta-thalassemia, giving CRSP a commercial revenue stream that few peers in gene editing can claim. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over recent weeks the stock has moved lower and hit fresh 52-week lows, even after reporting quarterly revenue growth above 1,300% year over year thanks to CASGEVY. Net losses have widened as the company invests in its pipeline, yet cash and investments sit in the $1.9 billion to $2.4 billion range, supporting several years of runway. Phase 1b cardiovascular data and early autoimmune results produced mixed market reactions. Analysts generally hold a Buy consensus, though near-term momentum remains soft.
Intellia Therapeutics focuses on in vivo CRISPR/Cas9 therapies, with lead programs in hereditary angioedema (lonvo-z) and ATTR amyloidosis (nex-z). It works with partners including Regeneron and Novartis. Unlike CRSP, NTLA has no approved product yet, though it is moving toward a potential first approval with a BLA for lonvo-z under priority review.
Market action has been choppy. The stock rose after the FDA lifted a clinical hold on the late-stage MAGNITUDE-2 study, then retreated following a quarterly report that showed sharply lower revenue year over year and a wider net loss. Completion of enrollment in a Phase 3 ATTR trial and positive long-term follow-up data have kept the pipeline story alive, but the share price stays well below its 52-week high. The analyst consensus sits at Hold, balancing optimism on late-stage catalysts with caution around ongoing losses and execution risks.
The main difference comes down to commercialization. CRSP already recognizes revenue from an approved therapy, while NTLA is still pre-revenue at scale and depends on future regulatory milestones. CRSP also carries a larger market capitalization and stronger cash reserves, which support a longer development runway. NTLA’s smaller balance sheet relative to its losses makes it more sensitive to financing needs.
Growth drivers differ as well. CRSP’s near-term outlook centers on CASGEVY adoption and further pipeline readouts, while NTLA’s rests on potential approval and launch of lonvo-z plus progress in ATTR. Risk profiles reflect these stages: CRSP contends with commercial execution and partnership revenue constraints, whereas NTLA faces binary regulatory and clinical outcomes. Recent momentum has been negative for both, though NTLA has shown sharper swings tied to its earlier stage and heavier reliance on single catalysts.
Looking at trend consistency, stability, catalysts, and relative positioning, Tickeron’s AI framework currently leans toward CRSP over NTLA. The commercial asset base, larger cash position, and steadier trend profile give CRSP a more consistent technical and fundamental footing. NTLA still offers meaningful upside linked to its late-stage pipeline, yet its greater volatility and dependence on binary events add uncertainty. This view is probabilistic and based on present conditions rather than a forecast of future returns.
When evaluating names like these, I sometimes turn to Tickeron’s AI Trading Bots to test how automated strategies are currently positioned across similar stocks. The platform offers a range of bots with different styles and timeframes, which can provide additional perspective on market behavior without replacing fundamental review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
NTLA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 86 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 44 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NTLA moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 22 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 206 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
NTLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 111 of 128 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.186) is normal, around the industry mean (3.592). P/E Ratio (-3.398) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary, potentially curative therapeutics
Industry Biotechnology